ASH Annual Meeting   |  December 17, 2019   Stephen M. Ansell, MD, PhD, on Progress of CAR T-Cell Therapy At the 2019 ASH Annual Meeting, Stephen M. Ansell, MD, PhD, from Mayo Clinic, discussed a plenary session presentation focused on chimeric antigen receptor (CAR) T-cell therapy, and the excitement surround new bio-specific agents that will be available for patients. Read more advertisement   KTE-X19 CAR T-Cell Therapy Effective for Relapsed/Refractory Mantle Cell Lymphoma Results from the ZUMA-II trial indicated that patients with relapsed/refractory mantle cell lymphoma resistant to prior therapies may benefit from treatment with KTE-X19, an autologous CD19-targeting CAR T-cell therapy. Read more